Showing posts with label Aurobindo Pharma. Show all posts
Showing posts with label Aurobindo Pharma. Show all posts

Thursday, 23 June 2016

Leave or Remain: Britain votes on EU membership today



World leaders all the way from US President Barack Obama to Indian Prime Minister Narendra Modi, and not least the leaders of European countries, want Britain to remain in the European Union (EU). For more update visit www.marketmagnify.com/stock-cash-tips.php & Give a missed call @ 78-79-88-11-22.

           Brexit: Which Indian IT cos may gain or fall on EU referendum
 Bank of America Merrill Lynch feels that Brexit may create recession risks that could hurt IT demand further hurting 10-14 percent revenue growth for the UK businesses of the Indian IT companies in FY17.
              Brexit fears are totally overblown: Jim Cramer
Jim Cramer's jaw dropped to the floor by how overblown Brexit fears are when he read the op-ed by Matt Ridley in the Wall Street Journal entitled "The Business Case for Brexit.
             The Brexit conundrum: To be or not to be
 There's been a lot of talk around whether or not Britons will vote to stay in the European Union. Brexit, as it is called, will have repercussions on the UK, the EU as well as emerging markets like India. The referendum is set for June 23. Here is a look at how it would play out and what impact, if any, it would have on countries and currencies.
                Brexit will mean risk-off in EMs; India could be hurt too: LGM
The biggest casualty of a ‘leave’ vote would be the pound and the UK stock market which could fall as much as 5-10 percent feels Chowdhry
                 Lupin gets USFDA nod for fungal infection drug
Company's US subsidiary Gavis Pharmaceuticals LLC has received final approvals to market "its Voriconazole tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL from the United States Food and Drug Administration (FDA)," Lupin said in a filing to BSE
                KEC International gains 7% on order win worth Rs 1036 crore
The company's transmission and distribution business has received an order worth Rs 666 crore in    
                    Drug to treat eye disease won't hit mkt before 2-3 yrs: Biocon
Early trials have indicated a positive data for the drug QPI-1007 to treat nonarteritic anterior ischemic optic neuropathy (NAION), says Kiran Mazumdar Shaw, CMD of Boicon.

Monday, 23 May 2016

Today's Stocks In News


Share prices of Ujaas Energy rose 16 percent intraday Monday on the back of strong fourth quarter numbers declared by the company. For more information visit www.marketmagnify.com/stock-cash-power.php
The company's Q4 net profit was up 76.9 percent at Rs 13.8 crore versus Rs 7.8 crore, in the same quarter last fiscal.
           The total income of the company has increased by 234 percent at Rs 167 crore versus Rs 50 crore. The EBITDA was up at Rs 30 crore versus Rs 15.9 crore, while EBITDA margin was down 1380 bps at 18 percent versus 31.8 percent.

         The company has approved the fund raising through FPO/ADR/GDR/QIP in its meeting held on May 21, 2016.
Equity benchmarks rebounded sharply on Monday morning with the Sensex rising 180.90 points to 25482.80. 
     The Nifty reclaimed 7800 level, up 64.25 points or 0.83 percent at 7813.95.

       ITC topped buying list on Sensex, up more than 6 percent after brokerages turned upbeat on the stock post quarterly earnings. Citi has upgraded the stock to buy from neutral and raised target price to Rs 390 from Rs 335.

          Tata Power gained 1.5 percent ahead of March quarter earnings. Adani Ports, ICICI Bank, HUL, SBI, Hindalco and Aurobindo Pharma were other early gainers while HDFC, Lupin, NTPC and GAIL were losers.

       The Indian rupee gained in the early trade today. It has opened higher by 14 paise at 67.30 per dollar against 67.44 Friday.